CONCORD BIOTECH
|
The Current P/E Ratio of CONCORD BIOTECH is 56.90.
| Share Price | ₹1,469.7 | Sep 08,2026 |
| Market Cap | ₹15,373.1 Cr | |
| Earnings-TTM | ₹270.2 Cr | TTM-Consolidated Results |
| Price/Earnings | 56.90x | Calculated as Market Cap/Earnings |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PE (Price/Earnings) ratio of CONCORD BIOTECH
P/E =
Market Capitalization
/ Net Income
or, using per-share numbers:
P/E = Stock Price /
Earnings Per Share (EPS)
Current Market Cap [ ₹15,373.1 Cr] as on Sep 08,2026
(/) Earnings [ ₹270.2 Cr] based on TTM-Consolidated Results
(=) P/E Ratio [ 56.90x ]
Thus, for CONCORD BIOTECH , the investors are currently willing to pay 56.90 times earnings to own 1 share of the company.
PE Multiples are the most widely used valuation multiple in practice.
Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.
In such cases, you may consider using Price to Book ratio or Price to Sales ratio of CONCORD BIOTECH !
P/E ratios, also, would not adjust for differences in the capital structure between companies.
The chart below summarizes the trend in P/E Ratio of CONCORD BIOTECH over the last five years.
Historical PE (Price/Earnings) ratio chart of CONCORD BIOTECH
PE Ratio Performance Analysis for CONCORD BIOTECH
- CONCORD BIOTECH 's p/e ratio for fiscal years ending Mar2026 to Mar2022 averaged 27.92x.
- CONCORD BIOTECH 's operated at median p/e ratio of 40.73x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, CONCORD BIOTECH 's p/e ratio peaked in Mar2024 at 51.68x.
- CONCORD BIOTECH 's p/e ratio hit its five-year low in Mar2023 of 0x.
How does CONCORD BIOTECH 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Earnings-TTM (Cr) | PE Ratio | Market Cap |
|---|---|---|---|
| CONCORD BIOTECH | 270.18 | 56.90 | 15,373.1 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 12,172.70 | 37.08 | 451,339.0 |
| DIVIS LABORATORIES LTD | 2,925.00 | 86.86 | 254,068.0 |
| TORRENT PHARMACEUTICALS LTD | 2,156.00 | 87.55 | 188,767.0 |
| CIPLA LTD | 3,364.84 | 33.23 | 111,804.0 |
| DR REDDYS LABORATORIES LTD | 3,169.30 | 30.33 | 96,113.4 |
| MANKIND PHARMA LTD | 2,055.11 | 46.34 | 95,242.0 |
| LUPIN LTD | 5,551.01 | 17.40 | 96,574.5 |
| ZYDUS LIFESCIENCES LTD | 4,492.20 | 25.54 | 114,713.0 |
| AUROBINDO PHARMA LTD | 3,712.74 | 26.13 | 97,008.7 |
| LAURUS LABS LTD | 1,090.76 | 96.37 | 105,118.0 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs CONCORD BIOTECH 's P/E Ratio
| Top 10 Industry Peers | PE Ratio |
|---|---|
| Min industry PE | 17.40x |
| Max industry PE | 96.37x |
| Median industry PE | 37.08x |
| Average industry PE | 49.43x |
You may also like the below Video Courses